Today Baymatob welcomes the formal appointment of Tony Barclay and Alwyn Reynolds to our Board of Directors. Baymatob has been lucky enough to benefit from both Tony and Alwyn’s impressive and complimentary expertise in an advisory capacity to date, with their formal appointments reflecting the value we already know they deliver. These strategic appointments come at a significant time for Baymatob, where we are implementing our clinical and commercial strategies, and builds on our momentum towards bringing our first product to market based upon our growing and compelling body of clinical evidence. We are excited to welcome our new board directors who will help us achieve our vision of transforming health outcomes for mothers and their babies, by leveraging our platform technology, Oli™.
Tony Barclay brings over 30 years’ experience in business, specifically in finance, risk management, product development, governance, manufacturing and international operations. Tony was CFO and Company Secretary of Fisher & Paykel Healthcare (FPH), from 2001 to 2018 and worked for the company for a total of 22 years. During this time Fisher & Paykel Healthcare grew to be one of the largest and most successful companies on the NZX, growing from a relatively small base to the current market capitalisation of approximately $18B. Prior to Fisher & Paykel Healthcare Tony worked in a number of finance roles for Arnott’s Biscuits and for Price Waterhouse, both in New Zealand and overseas. Tony is one of New Zealand’s most experienced and capable finance professionals with an extensive background that is highly relevant. Tony also serves as Chair of the board for Izon Science and as a Director for Veriphi a New Zealand based Med Tech start up.
Tony Barclay brings over 30 years’ experience in business, specifically in finance, risk management, product development, governance, manufacturing and international operations. Tony was CFO and Company Secretary of Fisher & Paykel Healthcare (FPH), from 2001 to 2018 and worked for the company for a total of 22 years. During this time Fisher & Paykel Healthcare grew to be one of the largest and most successful companies on the NZX, growing from a relatively small base to the current market capitalisation of approximately $18B. Prior to Fisher & Paykel Healthcare Tony worked in a number of finance roles for Arnott’s Biscuits and for Price Waterhouse, both in New Zealand and overseas. Tony is one of New Zealand’s most experienced and capable finance professionals with an extensive background that is highly relevant. Tony also serves as Chair of the board for Izon Science and as a Director for Veriphi a New Zealand based Med Tech start up.
Alwyn Reynolds, is a successful manager across various healthcare segments in Australia, Asia, and US for forty years. Co-Founder of Australian Diagnostics Pty. Ltd. a distributor of a range of pathology reagents and instrumentation that grew to 40 million AUD over ten years and was eventually acquired by Ciba Corning (Novartis). Alwyn served as Regional Marketing Head, Asia for Ciba Corning Diagnostics based in HK for four years before becoming Worldwide Marketing Manager - Critical Care Products, based in Boston, USA. Returning to Australia in 1999, Alwyn managed ATL (Advanced Technology Laboratories) Australia Pty. Ltd., then market leader in ultrasound with revenue of greater than 40 million AUD. Alwyn was appointed CEO of Imaxeon Pty. Ltd., a small medical device start-up, growing the company from 3 to 55 million AUD between 2001 and 2017, and establishing absolute market leadership in the contrast injection market in CT, MR, and Angiography in Australia. Alwyn brings the key skills of strategic planning, sales and marketing and general management in the medical device business.
Alwyn Reynolds, is a successful manager across various healthcare segments in Australia, Asia, and US for forty years. Co-Founder of Australian Diagnostics Pty. Ltd. a distributor of a range of pathology reagents and instrumentation that grew to 40 million AUD over ten years and was eventually acquired by Ciba Corning (Novartis). Alwyn served as Regional Marketing Head, Asia for Ciba Corning Diagnostics based in HK for four years before becoming Worldwide Marketing Manager - Critical Care Products, based in Boston, USA. Returning to Australia in 1999, Alwyn managed ATL (Advanced Technology Laboratories) Australia Pty. Ltd., then market leader in ultrasound with revenue of greater than 40 million AUD. Alwyn was appointed CEO of Imaxeon Pty. Ltd., a small medical device start-up, growing the company from 3 to 55 million AUD between 2001 and 2017, and establishing absolute market leadership in the contrast injection market in CT, MR, and Angiography in Australia. Alwyn brings the key skills of strategic planning, sales and marketing and general management in the medical device business.